An innovative tailored CAR T cell-redirecting immunotherapy for the treatment of metastatic and refractory Ewing Sarcoma
Klinische Pädiatrie · 01.05.2024 · 236 (03) · 210
DOI: 10.1055/s-0044-1786604 ↗Kurz gefasst
Fachartikel in der Zeitschrift Klinische Pädiatrie, erschienen am 01.05.2024. Verfasst von C Panisello und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Ewing Sarcoma (ES) stands as the second most common bone and soft tissue sarcoma affecting children and young adults. Limited response rates to current multimodal therapies and the lack of actionable targets contribute to dismal long-term survival in patients with metastatic/refractory disease. This highlights the urgent need for developing novel therapeutic approaches. Immunotherapy employing chimeric antigen receptor (CAR)T-cells directed against a tumour-associated antigen (TAA) is a promising therapy with a safe and efficient profile in B-cell malignancies. However, the development of efficient and safe CAR T-cells for the treatment of ES remains challenging due to i) the low abundance of specific and safe TAAs, ii) and the presence of an immunosuppressive tumour microenvironment (iTME) that limits CAR T-cells function. Here, we present an efficient CAR T-cell approach targeting a specific ES-associated antigens with limited expression in healthy tissues. We functionally validated its specificity and safety profiles in robust in vitro and in vivo assays using ES cell lines, primary cells, 3D sarcoma spheroids models which mimic the ES-iTME, and patient-derived animal models. Publication History Article published online: 10 May 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Panisello, C., Aschero, R., Roca-Ho, H., Martínez, A., Ramírez, C. C., Álava, E. D., Carcaboso, A. M., Bueno, C., & Menéndez, P. (2024). An innovative tailored CAR T cell-redirecting immunotherapy for the treatment of metastatic and refractory Ewing Sarcoma. Klinische Pädiatrie, 236(03), 210. https://doi.org/10.1055/s-0044-1786604
Vancouver
Panisello C, Aschero R, Roca-Ho H, Martínez A, Ramírez CC, Álava ED, et al. An innovative tailored CAR T cell-redirecting immunotherapy for the treatment of metastatic and refractory Ewing Sarcoma. Klinische Pädiatrie. 2024;236(03):210. doi:10.1055/s-0044-1786604
BibTeX
@article{Panisello2024,
author = {Panisello, C and Aschero, R and Roca-Ho, H and Martínez, A and Ramírez, C Castilla and Álava, E de and Carcaboso, A M and Bueno, C and Menéndez, P},
title = {An innovative tailored CAR T cell-redirecting immunotherapy for the treatment of metastatic and refractory Ewing Sarcoma},
journal = {Klinische Pädiatrie},
year = {2024},
volume = {236},
number = {03},
pages = {210},
doi = {10.1055/s-0044-1786604}
}
EUVIMED